ImageneBio (NASDAQ:IMA – Get Free Report) and Stoke Therapeutics (NASDAQ:STOK – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability.
Insider and Institutional Ownership
75.0% of ImageneBio shares are owned by institutional investors. 2.2% of ImageneBio shares are owned by company insiders. Comparatively, 9.6% of Stoke Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares ImageneBio and Stoke Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ImageneBio | N/A | -38.99% | -34.84% |
| Stoke Therapeutics | -753.60% | -59.36% | -51.46% |
Risk & Volatility
ImageneBio has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations for ImageneBio and Stoke Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ImageneBio | 2 | 0 | 1 | 1 | 2.25 |
| Stoke Therapeutics | 1 | 0 | 10 | 0 | 2.82 |
ImageneBio presently has a consensus target price of $29.00, suggesting a potential upside of 616.05%. Stoke Therapeutics has a consensus target price of $44.25, suggesting a potential upside of 72.18%. Given ImageneBio’s higher probable upside, equities analysts clearly believe ImageneBio is more favorable than Stoke Therapeutics.
Earnings and Valuation
This table compares ImageneBio and Stoke Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ImageneBio | $800,000.00 | 57.46 | -$45.35 million | ($4.58) | -0.88 |
| Stoke Therapeutics | $184.42 million | 8.99 | -$6.89 million | ($3.34) | -7.69 |
Stoke Therapeutics has higher revenue and earnings than ImageneBio. Stoke Therapeutics is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.
About ImageneBio
ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
About Stoke Therapeutics
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Receive News & Ratings for ImageneBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImageneBio and related companies with MarketBeat.com's FREE daily email newsletter.
